Comparative Pharmacology
Head-to-head clinical analysis: VASOCON A versus VISINE L R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASOCON A versus VISINE L R.
VASOCON-A vs VISINE L.R.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antazoline is an H1-receptor antagonist that blocks histamine-induced vasodilation and increased capillary permeability. Naphazoline is a direct-acting alpha-adrenergic agonist that constricts conjunctival blood vessels, reducing redness and swelling.
Selective alpha-1 adrenergic receptor agonist; constricts conjunctival blood vessels via stimulation of alpha-1 adrenoreceptors in the ophthalmic artery, reducing redness and edema.
Adults: 1-2 drops in each nostril every 8-12 hours, not to exceed 2 doses per day. Do not use for more than 3 consecutive days.
1 to 2 drops in the affected eye(s) every 8 to 12 hours, not to exceed 2 drops per eye every 8 hours. Ophthalmic solution 0.05%.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; extends to 12-18 hours in hepatic impairment.
Terminal elimination half-life is 2.1 ± 0.2 hours for the racemic mixture; clinical context: dosing intervals typically every 4-6 hours.
Renal excretion of unchanged drug: 60-80%; biliary/fecal: 20-40% as metabolites.
Primarily renal excretion of unchanged drug and metabolites; ~90% of an oral dose is excreted in urine within 24 hours; biliary/fecal excretion accounts for <5%.
Category C
Category C
Ophthalmic Decongestant/Antihistamine Combination
Ophthalmic Decongestant